JOSEPH III KLEIN
CIK 1206369 · last filed 2026-07-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.33M
Companies
8
Total Filings
145
Lifetime Open-Market Net
-$18.50M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IONS | Director | 22,633 | $53.41 | $1.21M | -$12.33M | 43 | 2026-07-06 |
| AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Director | — | — | — | $0 | 3 | 2020-10-13 |
| IONIS PHARMACEUTICALS INC (ISIS) Delisted | Director | 5,643 | — | — | -$3.38M | 21 | 2015-11-12 |
| SAVIENT PHARMACEUTICALS INC (SVNT) Delisted | Director | 17,388 | — | — | -$573.6K | 14 | 2010-07-21 |
| OSI PHARMACEUTICALS INC (OSIP) Delisted | Director | 0 | — | — | -$698.3K | 13 | 2010-06-09 |
| BMRN | Director | 35,000 | $60.59 | $2.12M | -$1.33M | 12 | 2010-03-10 |
| PDL BIOPHARMA, INC. (PDLI) Delisted | Director | 19,484 | — | — | -$36.2K | 26 | 2009-11-06 |
| NPS PHARMACEUTICALS INC (NPSP) Delisted | Director | 15,000 | — | — | -$154.7K | 4 | 2007-05-25 |
Recent Filings · Page 2 of 15
145 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-09-03 | IONS | Notice (144) | −28,000 | -$1.68M | EDGAR |
| 2025-07-02 | IONS | Grant (A) | — | $0 | EDGAR |
| 2024-07-17 | IONS | Mixed | — | -$307.0K | EDGAR |
| 2024-07-16 | IONS | Notice (144) | −12,000 | -$600.0K | EDGAR |
| 2024-07-03 | IONS | Grant (A) | — | $0 | EDGAR |
| 2024-05-07 | IONS | Sell (S) | −6,000 | -$256.3K | EDGAR |
| 2024-05-03 | IONS | Notice (144) | −6,000 | -$261.2K | EDGAR |
| 2023-11-17 | IONS | Sell (S) | −2,000 | -$100.0K | EDGAR |
| 2023-11-15 | IONS | Notice (144) | −2,000 | -$100.0K | EDGAR |
| 2023-09-28 | IONS | Sell (S) | −2,000 | -$90.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.